Abstract
Purpose
Aspirin, one of the most commonly used nonsteroidal anti-inflammatory drugs (NAIDS), not only shows cancer chemoprevention effects but also improves cancer therapeutic effects when combined with other therapies. Studies that focus on aspirin regulation of the hallmarks of cancer and the associated molecular mechanisms facilitate a more thorough understanding of aspirin in mediating chemoprevention and may supply additional information for the development of novel cancer therapeutic agents.
Methods
The relevant literatures from PubMed have been reviewed in this article.
Results
Current studies have revealed that aspirin regulates almost all the hallmarks of cancer. Within tumor tissue, aspirin suppresses the bioactivities of cancer cells themselves and deteriorates the tumor microenvironment that supports cancer progression. In addition to tumor tissues, blocking of platelet activation also contributes to the ability of aspirin to inhibit cancer progression. In terms of the molecular mechanism, aspirin targets oncogenes and cancer-related signaling pathways and activates certain tumor suppressors.
Conclusion
Beyond a chemopreventive agent, aspirin is a master regulator of the hallmarks of cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ai G, Dachineni R, Kumar DR, Marimuthu S, Alfonso LF, Bhat GJ (2016) Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53. Tumour Biol 37:6007–6016. https://doi.org/10.1007/s13277-015-4438-3
Alfonso LF, Srivenugopal KS, Arumugam TV, Abbruscato TJ, Weidanz JA, Bhat GJ (2009) Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol 34:597–608
Alfonso L, Ai G, Spitale RC, Bhat GJ (2014) Molecular targets of aspirin and cancer prevention. Br J Cancer 111:61–67. https://doi.org/10.1038/bjc.2014.271
Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13:518–527. https://doi.org/10.1016/s1470-2045(12)70112-2
Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81–106
Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A, Arosh JA (2009) Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms. Mol Endocrinol 23:1291–1305. https://doi.org/10.1210/me.2009-0017
Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM (2006) Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 20:2009–2016. https://doi.org/10.1096/fj.06-5987com
Bos CL et al (2006) Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene 25:6447–6456. https://doi.org/10.1038/sj.onc.1209658
Bottcher JP et al (2018) NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172:1022–1037. https://doi.org/10.1016/j.cell.2018.01.004
Boueroy P et al (2017) Inhibitory effect of aspirin on cholangiocarcinoma cells. APJCP 18:3091–3096. https://doi.org/10.22034/apjcp.2017.18.11.3091
Brighenti E et al (2016) Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate. Oncotarget 7:63226–63241. https://doi.org/10.18632/oncotarget.11441
Bronger H et al (2012) Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. BCR 14:30. https://doi.org/10.1186/bcr3115
Cao Y et al (2016a) Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. Gastroenterology 151:879–892.e874. https://doi.org/10.1053/j.gastro.2016.07.030
Cao Y et al (2016b) Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol 2:762–769. https://doi.org/10.1001/jamaoncol.2015.6396
Capodanno D, Angiolillo DJ (2016) Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation 134:1579–1594. https://doi.org/10.1161/circulationaha.116.023164
Castro-Sanchez L, Agra N, Llorente Izquierdo C, Motino O, Casado M, Bosca L, Martin-Sanz P (2013) Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma. Int J Biochem Cell Biol 45:2501–2511. https://doi.org/10.1016/j.biocel.2013.08.005
Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95:681–686
Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1–10. https://doi.org/10.1016/j.immuni.2013.07.012
Chen J, Stark LA (2017) Aspirin prevention of colorectal cancer: focus on NF-kappaB signalling and the nucleolus. Biomedicines 5:43. https://doi.org/10.3390/biomedicines5030043
Chen W, Zhu H, Jia Z, Li J, Misra HP, Zhou K, Li Y (2009) Inhibition of peroxynitrite-mediated DNA strand cleavage and hydroxyl radical formation by aspirin at pharmacologically relevant concentrations: implications for cancer intervention. Biochem Biophys Res Commun 390:142–147. https://doi.org/10.1016/j.bbrc.2009.09.083
Cheng Y, Li Y, Liu D, Zhang R, Zhang J (2014) miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway. FEBS Lett 588:3274–3281. https://doi.org/10.1016/j.febslet.2014.07.012
Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 30:3540–3544. https://doi.org/10.1200/jco.2011.41.0308
Choi YR et al (2003) Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Can Res 63:2188–2193
Choi BH, Chakraborty G, Baek K, Yoon HS (2013) Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells. Exp Mol Med 45:e47. https://doi.org/10.1038/emm.2013.91
Coyle C et al (2016) ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials 51:56–64. https://doi.org/10.1016/j.cct.2016.10.004
Cuzick J et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501–507. https://doi.org/10.1016/s1470-2045(09)70035-x
Dahal K, Sharma SP, Kaur J, Anderson BJ, Singh G (2017) Efficacy and safety of proton pump inhibitors in the long-term aspirin users: a meta-analysis of randomized controlled trials. Am J Ther 24:e559–e569. https://doi.org/10.1097/mjt.0000000000000637
de Visser KE, Coussens LM (2006) The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 13:118–137. https://doi.org/10.1159/000092969
DeNardo DG, Andreu P, Coussens LM (2010) Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer Meta Rev 29:309–316. https://doi.org/10.1007/s10555-010-9223-6
Dhar SK, Lynn BC, Daosukho C, St Clair DK (2004) Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene. J Biol Chem 279:28209–28219. https://doi.org/10.1074/jbc.m403553200
Dibra HK, Brown JE, Hooley P, Nicholl ID (2010) Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line. Oncol Rep 24:37–46
Din FV, Dunlop MG, Stark LA (2004) Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 91:381–388. https://doi.org/10.1038/sj.bjc.6601913
Ding JH, Yuan LY, Huang RB, Chen GA (2014) Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF. Eur J Haematol 93:329–339. https://doi.org/10.1111/ejh.12352
Dong Xda E et al (2007) High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 30:596–606. https://doi.org/10.1097/cji.0b013e31804efc76
Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P (2012) Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals 5:1346–1371. https://doi.org/10.3390/ph5121346
Ekinci D, Senturk M, Kufrevioglu OI (2011) Salicylic acid derivatives: synthesis, features and usage as therapeutic tools. Expert Opin Ther Pat 21:1831–1841. https://doi.org/10.1517/13543776.2011.636354
Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676. https://doi.org/10.1038/nm0603-669
Finetti F et al (2012) Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis. PLoS ONE 7:e40576. https://doi.org/10.1371/journal.pone.0040576
Fink SP et al (2014) Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 6:233re232. https://doi.org/10.1126/scitranslmed.3008481
Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, Bullerdiek J (2001) Variation of HMGB1 expression in breast cancer. Anticancer Res 21:3881–3885
Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603–1613. https://doi.org/10.1016/s0140-6736(07)60747-8
Fukuda A et al (2011) Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19:441–455. https://doi.org/10.1016/j.ccr.2011.03.002
Gala MK, Chan AT (2015) Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment. Clin Cancer Res 21:1543–1548. https://doi.org/10.1158/1078-0432.ccr-14-0877
Gao M, Kong Q, Hua H, Yin Y, Wang J, Luo T, Jiang Y (2016) AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin. Oncotarget 7:16349–16361. https://doi.org/10.18632/oncotarget.7648
Gao M, Guo KM, Wei YM, Ma MM, Cai JR, Xia TT, Ye QJ (2017a) Aspirin inhibits the proliferation of human uterine leiomyoma cells by downregulation of KRasp110alpha interaction. Oncol Rep 38:2507–2517. https://doi.org/10.3892/or.2017.5915
Gao P et al (2017b) The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. Oncotarget 8:69139–69161. https://doi.org/10.18632/oncotarget.19932
Gasic GJ, Gasic TB, Murphy S (1972) Anti-metastatic effect of aspirin. Lancet 2:932–933
Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR (2003) A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res 9:383–390
Gong J et al (2014) Combined targeting of STAT3/NF-kappaB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res 20:1259–1273. https://doi.org/10.1158/1078-0432.ccr-13-1664
Grancher A, Michel P, Di Fiore F, Sefrioui D (2018) Aspirin and colorectal cancer. Bull Cancer 105:171–180. https://doi.org/10.1016/j.bulcan.2017.09.013
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. https://doi.org/10.1016/j.cell.2010.01.025
Guillem-Llobat P, Dovizio M, Alberti S, Bruno A, Patrignani P (2014) Platelets, cyclooxygenases, and colon cancer. Semin Oncol 41:385–396. https://doi.org/10.1053/j.seminoncol.2014.04.008
Guillem-Llobat P et al (2016) Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget 7:32462–32477. https://doi.org/10.18632/oncotarget.8655
Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK (2018) The platelet lifeline to cancer: challenges and opportunities. Cancer Cell 33:965–983. https://doi.org/10.1016/j.ccell.2018.03.002
Hammerlindl H et al (2018) Acetylsalicylic acid governs the effect of sorafenib in RAS-mutant. Cancers Clin Cancer Res 24:1090–1102. https://doi.org/10.1158/1078-0432.Ccr-16-2118
Han Y et al (2019) Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis. Cancer Lett 440–441:116–125. https://doi.org/10.1016/j.canlet.2018.10.011
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hannen R, Bartsch JW (2018) Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett 592:2023–2031. https://doi.org/10.1002/1873-3468.13084
Hardie DG (2008) AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes 32(4):S7–12. https://doi.org/10.1038/ijo.2008.116
Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24:2899–2908. https://doi.org/10.1038/sj.onc.1208615
Hawley SA et al (2012) The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336:918–922. https://doi.org/10.1126/science.1215327
He H et al (2006) Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma. Cancer 106:1243–1249. https://doi.org/10.1002/cncr.21694
Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, Toker A (2017) Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling. Can Res 77:790–801. https://doi.org/10.1158/0008-5472.can-16-2400
Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M (2002) Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168:762–765
Howe LR et al (2013) Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. Prostaglandins Other Lipid Mediat 106:99–105. https://doi.org/10.1016/j.prostaglandins.2013.04.002
Hsu HH et al (2017) Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo colon cancer cells. Int J Mol Sci. https://doi.org/10.3390/ijms18061132
Hua H, Zhang H, Kong Q, Wang J, Jiang Y (2018a) Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev. https://doi.org/10.1002/med.21514
Hua H, Zhang H, Kong Q, Wang J, Jiang Y (2018b) Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev. https://doi.org/10.1002/med.21514
Huang SP, Wu MS, Shun CT, Wang HP, Hsieh CY, Kuo ML, Lin JT (2005) Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 12:229–241. https://doi.org/10.1007/s11373-004-8177-5
Huang L et al (2011) Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Can Res 71:7617–7627. https://doi.org/10.1158/0008-5472.can-11-2349
Huang D et al (2018) Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Meta Rev 37:173–187. https://doi.org/10.1007/s10555-017-9726-5
Jiang R, Wei L, Zhu M, Wu J, Wang L (2016) Aspirin inhibits LPS-induced expression of PI3K/Akt, ERK, NF-kappaB, CX3CL1, and MMPs in human bronchial epithelial cells. Inflammation 39:643–650. https://doi.org/10.1007/s10753-015-0289-8
Jin M, Li C, Zhang Q, Xing S, Kan X, Wang J (2018) Effects of aspirin on proliferation, invasion and apoptosis of Hep-2 cells via the PTEN/AKT/NF-kappaB/survivin signaling pathway. Oncol Lett 15:8454–8460. https://doi.org/10.3892/ol.2018.8377
Johnson KE et al (2019) Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis Blood advances 3:198–211. https://doi.org/10.1182/bloodadvances.2018026161
Karnoub AE, Weinberg RA (2006) Chemokine networks and breast cancer metastasis. Breast Dis 26:75–85
Kawada M et al (2006) Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer. Can Res 66:2913–2917. https://doi.org/10.1158/0008-5472.can-05-3460
Kawano M et al (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85. https://doi.org/10.1038/332083a0
Khan P et al (2016) Aspirin inhibits epithelial-to-mesenchymal transition and migration of oncogenic K-ras-expressing non-small cell lung carcinoma cells by down-regulating E-cadherin repressor Slug. BMC Cancer 16:39. https://doi.org/10.1186/s12885-016-2078-7
Khoo BL et al (2019) Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. Br J Cancer 120:407–423. https://doi.org/10.1038/s41416-018-0301-9
Kim SA, Roh JL, Kim SB, Choi SH, Nam SY, Kim SY (2018) Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up. Int J Clin Oncol 23:52–58. https://doi.org/10.1007/s10147-017-1165-3
Kisslov L, Hadad N, Rosengraten M, Levy R (2012) HT-29 human colon cancer cell proliferation is regulated by cytosolic phospholipase A(2)alpha dependent PGE(2)via both PKA and PKB pathways. Biochem Biophys Acta 1821:1224–1234. https://doi.org/10.1016/j.bbalip.2012.06.005
Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956–959
Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11:325–337. https://doi.org/10.1038/nrc3038
Kostadinov RL et al (2013) NSAIDs modulate clonal evolution in Barrett’s esophagus. PLoS Genet 9:e1003553. https://doi.org/10.1371/journal.pgen.1003553
Kotschy A et al (2016) The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538:477–482. https://doi.org/10.1038/nature19830
Kumar A, Singh SM (2012) Priming effect of aspirin for tumor cells to augment cytotoxic action of cisplatin against tumor cells: implication of altered constitution of tumor microenvironment, expression of cell cycle, apoptosis, and survival regulatory molecules. Mol Cell Biochem 371:43–54. https://doi.org/10.1007/s11010-012-1421-9
Kumar D et al (2018) Aspirin suppresses PGE2 and activates AMP kinase to inhibit melanoma cell motility, pigmentation, and selective tumor growth in vivo. Cancer Prev Res 11:629–642. https://doi.org/10.1158/1940-6207.Capr-18-0087
Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590. https://doi.org/10.1016/j.ccr.2011.09.009
Lai TS, Davies C, Greenberg CS (2010) Human tissue transglutaminase is inhibited by pharmacologic and chemical acetylation. Protein Sci 19:229–235. https://doi.org/10.1002/pro.301
Lavie CJ, Howden CW, Scheiman J, Tursi J (2017) Upper gastrointestinal toxicity associated with long-term aspirin therapy: consequences and prevention. Curr Probl Cardiol 42:146–164. https://doi.org/10.1016/j.cpcardiol.2017.01.006
Law BK, Waltner-Law ME, Entingh AJ, Chytil A, Aakre ME, Norgaard P, Moses HL (2000) Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. The Journal of biological chemistry 275:38261–38267. https://doi.org/10.1074/jbc.m005545200
Lee M, Gibbs P (2015) RE: aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst 107:1. https://doi.org/10.1093/jnci/djv149
Li LF, Wei ZJ, Sun H, Jiang B (2014) Abnormal beta-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis. World J Gastroenterol 20:12313–12321. https://doi.org/10.3748/wjg.v20.i34.12313
Li L et al (2016) Aspirin inhibits growth of ovarian cancer by upregulating caspase-3 and downregulating bcl-2. Oncol Lett 12:93–96. https://doi.org/10.3892/ol.2016.4607
Liao X et al (2012) Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367:1596–1606. https://doi.org/10.1056/nejmoa1207756
Liao D et al (2015) Aspirin suppresses the growth and metastasis of osteosarcoma through the NF-kappaB pathway. Clin Cancer Res 21:5349–5359. https://doi.org/10.1158/1078-0432.ccr-15-0198
Liu Y (2018) Targeting myeloid-derived suppressor cells for cancer immunotherapy. CII 67:1181–1195. https://doi.org/10.1007/s00262-018-2175-3
Liu YX et al (2019) Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism. Acta Pharmacol Sin 40:122–132. https://doi.org/10.1038/s41401-018-0014-x
Loch T, Michalski B, Mazurek U, Graniczka M (2001) Vascular endothelial growth factor (VEGF) and its role in neoplastic processes. Postepy higieny i medycyny doswiadczalnej 55:257–274
Loo TM et al (2017) Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov 7:522–538. https://doi.org/10.1158/2159-8290.cd-16-0932
Ma X, Aoki T, Tsuruyama T, Narumiya S (2015) Definition of prostaglandin E2-EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth. Can Res 75:2822–2832. https://doi.org/10.1158/0008-5472.can-15-0125
Maisonpierre PC et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55–60
Maity G, Chakraborty J, Ghosh A, Haque I, Banerjee S, Banerjee SK (2019) Aspirin suppresses tumor cell-induced angiogenesis and their incongruity. J Cell Commun Signal. https://doi.org/10.1007/s12079-018-00499-y
Majumder M et al (2016) COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis. Stem cells 34:2290–2305. https://doi.org/10.1002/stem.2426
Majumder M et al (2018) COX-2 induces oncogenic micro RNA miR655 in human breast cancer. Sci Rep 8:327. https://doi.org/10.1038/s41598-017-18612-3
Mandal P (2018) Molecular mechanistic pathway of colorectal carcinogenesis associated with intestinal microbiota. Anaerobe 49:63–70. https://doi.org/10.1016/j.anaerobe.2017.12.008
Markowitz SD (2007) Aspirin and colon cancer–targeting prevention? New Engl J Med 356:2195–2198. https://doi.org/10.1056/NEJMe078044
Masuda M et al (2002) Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Can Res 62:3351–3355
McNeil JJ et al (2018a) Effect of aspirin on all-cause mortality in the healthy elderly. New Engl J Med 379:1519–1528. https://doi.org/10.1056/NEJMoa1803955
McNeil JJ et al (2018b) Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 379:1509–1518. https://doi.org/10.1056/NEJMoa1805819
McNeil JJ et al (2018c) Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 379:1499–1508. https://doi.org/10.1056/NEJMoa1800722
Meyer B et al (2004) Expression pattern of the HMGB1 gene in sarcomas of the dog. Anticancer Res 24:707–710
Mitchell AG, Broadhead JF (1967) Hydrolysis of solubilized aspirin. J Pharm Sci 56:1261–1266
Mitrugno A, Sylman JL, Ngo AT, Pang J, Sears RC, Williams CD, McCarty OJ (2017) Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. Am J Physiol Cell Physiol 312:C176–c189. https://doi.org/10.1152/ajpcell.00196.2016
Morikawa T et al (2011) STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 17:1452–1462. https://doi.org/10.1158/1078-0432.ccr-10-2694
Moss WN (2013) Computational prediction of RNA secondary structure. Methods Enzymol 530:3–65. https://doi.org/10.1016/b978-0-12-420037-1.00001-4
Na YR, Yoon YN, Son DI, Seok SH (2013) Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS ONE 8:e63451. https://doi.org/10.1371/journal.pone.0063451
Nakanishi M, Rosenberg DW (2013) Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol 35:123–137. https://doi.org/10.1007/s00281-012-0342-8
Navone SE et al (2018) Aspirin affects tumor angiogenesis and sensitizes human glioblastoma endothelial cells to temozolomide, bevacizumab, and sunitinib, impairing vascular endothelial growth factor-related signaling. World Neurosurg. https://doi.org/10.1016/j.wneu.2018.08.080
Netea MG, Puren AJ, Dinarello CA (2000) A short course of oral aspirin increases IL-18-induced interferon-gamma production in whole blood cultures. Eur Cytokine Netw 11:379–382
Ng K et al (2015) Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst 107:345. https://doi.org/10.1093/jnci/dju345
Nunez L, Valero RA, Senovilla L, Sanz-Blasco S, Garcia-Sancho J, Villalobos C (2006) Cell proliferation depends on mitochondrial Ca2+ uptake: inhibition by salicylate. J Physiol 571:57–73. https://doi.org/10.1113/jphysiol.2005.100586
Nunez F, Bravo S, Cruzat F, Montecino M, De Ferrari GV (2011) Wnt/beta-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells. PLoS ONE 6:e18562. https://doi.org/10.1371/journal.pone.0018562
O’Callaghan G, Houston A (2015) Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol 172:5239–5250. https://doi.org/10.1111/bph.13331
Okada S et al (2018) Effect of aspirin on cancer chemoprevention in Japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial. Diabetes Care 41:1757–1764. https://doi.org/10.2337/dc18-0368
Osborn L, Kunkel S, Nabel GJ (1989) Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 86:2336–2340
Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ (Clinical research ed) 299:1247–1250
Paganini-Hill A, Hsu G, Ross RK, Henderson BE (1991) Aspirin use and incidence of large-bowel cancer in a California retirement community. J Natl Cancer Inst 83:1182–1183
Paganini-Hill A, Hsu G, Ross RK, Henderson BE (1992) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 326:1290
Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD (2014) Immune modulation in cancer with antibodies. Annu Rev Med 65:185–202. https://doi.org/10.1146/annurev-med-092012-112807
Pan MR, Chang HC, Hung WC (2008) Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal 20:1134–1141. https://doi.org/10.1016/j.cellsig.2008.02.004
Parida S, Pal I, Parekh A, Thakur B, Bharti R, Das S, Mandal M (2016) GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling. Cell Death Dis 7:e2154. https://doi.org/10.1038/cddis.2016.61
Pathi S, Jutooru I, Chadalapaka G, Nair V, Lee SO, Safe S (2012) Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors. PLoS ONE 7:e48208. https://doi.org/10.1371/journal.pone.0048208
Patrignani P, Patrono C (2016) Aspirin and cancer. J Am Coll Cardiol 68:967–976. https://doi.org/10.1016/j.jacc.2016.05.083
Pavon-Romero GF, Ramirez-Jimenez F, Roldan-Alvarez MA, Teran LM, Falfan-Valencia R (2017) Physiopathology and genetics in aspirin-exacerbated respiratory disease. Exp Lung Res 43:327–335. https://doi.org/10.1080/01902148.2017.1358776
Perkins ND (2012) The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 12:121–132. https://doi.org/10.1038/nrc3204
Phillips RJ, Fortier MA, Lopez Bernal A (2014) Prostaglandin pathway gene expression in human placenta, amnion and choriodecidua is differentially affected by preterm and term labour and by uterine inflammation. BMC Preg Childb 14:241. https://doi.org/10.1186/1471-2393-14-241
Pinckard RN, Hawkins D, Farr RS (1968) In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 219:68–69
Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, McConkey DJ (2005) Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther 4:1263–1269
Pique M, Barragan M, Dalmau M, Bellosillo B, Pons G, Gil J (2000) Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett 480:193–196
Plantureux L, Crescence L, Dignat-George F, Panicot-Dubois L, Dubois C (2018) Effects of platelets on cancer progression. Thromb Res 164(Suppl 1):S40–s47. https://doi.org/10.1016/j.thromres.2018.01.035
Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39–51. https://doi.org/10.1016/j.cell.2010.03.014
Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437. https://doi.org/10.1038/nm.3394
Rachidi S, Metelli A (2017) Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis. Sci Immunol. https://doi.org/10.1126/sciimmunol.aai7911
Rachidi S et al (2017) Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis. Sci Immunol 2:1. https://doi.org/10.1126/sciimmunol.aai7911
Ramjiawan RR, Griffioen AW, Duda DG (2017) Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis 20:185–204. https://doi.org/10.1007/s10456-017-9552-y
Rocha S, Campbell KJ, Perkins ND (2003) p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell 12:15–25
Rogers MAM, Aronoff DM (2016) The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect 22:178.e171–178.e179. https://doi.org/10.1016/j.cmi.2015.10.003
Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741–1750. https://doi.org/10.1016/s0140-6736(10)61543-7
Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet (London, England) 379:1591–1601. https://doi.org/10.1016/s0140-6736(12)60209-8
Rowland M, Riegelman S, Harris PA, Sholkoff SD, Eyring EJ (1967) Kinetics of acetylsalicylic acid disposition in man. Nature 215:413–414
Ruan YC et al (2012) Activation of the epithelial Na+ channel triggers prostaglandin E(2) release and production required for embryo implantation. Nat Med 18:1112–1117. https://doi.org/10.1038/nm.2771
Santilli F, Boccatonda A, Davi G (2016) Aspirin, platelets, and cancer: the point of view of the internist. Eur J Inter Med 34:11–20. https://doi.org/10.1016/j.ejim.2016.06.004
Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 169:361–371. https://doi.org/10.1016/j.cell.2017.03.035
Schror K (2011) Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol 25:473–484. https://doi.org/10.1016/j.bpg.2011.10.016
Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science (New York, NY) 348:56–61. https://doi.org/10.1126/science.aaa8172
Shehzad A, Lee J, Lee YS (2015) Autocrine prostaglandin E(2) signaling promotes promonocytic leukemia cell survival via COX-2 expression and MAPK pathway. BMB Rep 48:109–114
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Can Res 58:362–366
Shi C, Zhang N, Feng Y, Cao J, Chen X, Liu B (2017) Aspirin inhibits IKK-beta-mediated prostate cancer cell invasion by targeting matrix metalloproteinase-9 and urokinase-type plasminogen activator. Cell Physiol Biochem 41:1313–1324. https://doi.org/10.1159/000464434
Slee EA, O’Connor DJ, Lu X (2004) To die or not to die: how does p53 decide? Oncogene 23:2809–2818. https://doi.org/10.1038/sj.onc.1207516
Sostres C, Lanas A (2015) Epidemiology of low dose aspirin damage in the lower gastrointestinal tract. Curr Pharm Des 21:5094–5100
Spitz GA, Furtado CM, Sola-Penna M, Zancan P (2009) Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity. Biochem Pharmacol 77:46–53. https://doi.org/10.1016/j.bcp.2008.09.020
Stark LA, Dunlop MG (2005) Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis. Mol Cell Biol 25:5985–6004. https://doi.org/10.1128/mcb.25.14.5985-6004.2005
Stark LA, Din FV, Zwacka RM, Dunlop MG (2001) Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 15:1273–1275
Stegner D, Dutting S, Nieswandt B (2014) Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res 133(Suppl 2):S149–157. https://doi.org/10.1016/s0049-3848(14)50025-4
Sun L, Liu J, Cui D, Li J, Yu Y, Ma L, Hu L (2010) Anti-inflammatory function of withangulatin A by targeted inhibiting COX-2 expression via MAPK and NF-kappaB pathways. J Cell Biochem 109:532–541. https://doi.org/10.1002/jcb.22430
Sun X et al (2014) Regulation of miR-101/miR-199a-3p by the epithelial sodium channel during embryo implantation: involvement of CREB phosphorylation. Reproduction (Cambridge, England) 148:559–568. https://doi.org/10.1530/rep-14-0386
Sweet T, Khalili K, Sawaya BE, Amini S (2003) Identification of a novel protein from glial cells based on its ability to interact with NF-kappaB subunits. J Cell Biochem 90:884–891. https://doi.org/10.1002/jcb.10701
Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter TD, Paleolog E, Wheeler-Jones CP (2006) Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem 281:11792–11804. https://doi.org/10.1074/jbc.m509292200
Tang D, Kang R, Zeh HJ 3rd, Lotze MT (2010) High-mobility group box 1 and cancer. Biochem Biophys Acta 1799:131–140. https://doi.org/10.1016/j.bbagrm.2009.11.014
Tatham MH, Cole C, Scullion P, Wilkie R, Westwood NJ, Stark LA, Hay RT (2017) A proteomic approach to analyze the aspirin-mediated lysine acetylome. MCP 16:310–326. https://doi.org/10.1074/mcp.O116.065219
Thoms HC, Loveridge CJ, Simpson J, Clipson A, Reinhardt K, Dunlop MG, Stark LA (2010) Nucleolar targeting of RelA(p65) is regulated by COMMD1-dependent ubiquitination. Can Res 70:139–149. https://doi.org/10.1158/0008-5472.can-09-1397
Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9:259–267. https://doi.org/10.1038/nrclinonc.2011.199
Tian Y et al (2011) Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int J Colorectal Dis 26:13–22. https://doi.org/10.1007/s00384-010-1060-0
Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN (2006) Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38:1654–1661. https://doi.org/10.1016/j.biocel.2006.03.021
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716
Uddin S et al (2010) Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 126:382–394. https://doi.org/10.1002/ijc.24757
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232–235
Wang J et al (2017) Dehydrocostus lactone, a natural sesquiterpene lactone, suppresses the biological characteristics of glioma, through inhibition of the NF-kappaB/COX-2 signaling pathway by targeting IKKbeta. Am J Cancer Res 7:1270–1284
Weissmann G, Montesinos MC, Pillinger M, Cronstein BN (2002) Non-prostaglandin effects of aspirin III and salicylate: inhibition of integrin-dependent human neutrophil aggregation and inflammation in COX 2- and NF kappa B (P105)-knockout mice. Adv Exp Med Biol 507:571–577
Wong BC, Zhu GH, Lam SK (1999) Aspirin induced apoptosis in gastric cancer cells. Biomed Pharmacother 53:315–318. https://doi.org/10.1016/s0753-3322(00)88503-0
Wu Y, Wang Z, Kong J, Zhang J, Ling R (2017) Aspirin inhibits the proliferation of breast cancer cells via inducing apoptosis and autophagy. Xi bao yu fen zi mian yi xue za zhi 33:1348–1353
Xu XR, Yousef GM, Ni H (2018) Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood 131:1777–1789. https://doi.org/10.1182/blood-2017-05-743187
Yang H et al (2015) Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis 6:e1786. https://doi.org/10.1038/cddis.2015.153
Yeung KT, Yang J (2017) Epithelial–mesenchymal transition in tumor metastasis. Mol Oncol 11:28–39. https://doi.org/10.1002/1878-0261.12017
Yiannakopoulou E (2014) Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents—implications for cancer treatment and chemoprevention. Cell Oncol 37:167–178. https://doi.org/10.1007/s13402-014-0175-7
Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77–80. https://doi.org/10.1038/23948
Yue W, Yang CS, DiPaola RS, Tan XL (2014) Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res 7:388–397. https://doi.org/10.1158/1940-6207.capr-13-0337
Zang S et al (2017) PGE2 synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma. Hum Pathol 63:120–127. https://doi.org/10.1016/j.humpath.2017.02.018
Zelenay S et al (2015) Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162:1257–1270. https://doi.org/10.1016/j.cell.2015.08.015
Zeng ZS, Cohen AM, Guillem JG (1999) Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 20:749–755
Zhang X, Morham SG, Langenbach R, Young DA (1999) Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190:451–459
Zhang D, Bai B, Xi Y, Zhao Y (2016a) Can aspirin reduce the risk of endometrial cancer?: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer 26:1111–1120. https://doi.org/10.1097/igc.0000000000000731
Zhang S, Bian H, Li X, Wu H, Bi Q, Yan Y, Wang Y (2016b) Hydrogen sulfide promotes cell proliferation of oral cancer through activation of the COX2/AKT/ERK1/2 axis. Oncol Rep 35:2825–2832. https://doi.org/10.3892/or.2016.4691
Zhang H et al (2018) Aspirin inhibits natural killer/T-cell lymphoma by modulation of VEGF expression and mitochondrial function. Front Oncol 8:679. https://doi.org/10.3389/fonc.2018.00679
Zhao Q, Wang Z, Wang Z, Wu L, Zhang W (2016) Aspirin may inhibit angiogenesis and induce autophagy by inhibiting mTOR signaling pathway in murine hepatocarcinoma and sarcoma models. Oncol Lett 12:2804–2810. https://doi.org/10.3892/ol.2016.5017
Zimmermann KC, Waterhouse NJ, Goldstein JC, Schuler M, Green DR (2000) Aspirin induces apoptosis through release of cytochrome c from mitochondria. Neoplasia 2:505–513
Zou S, Fang L, Lee MH (2018) Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol Rep 6:1–12. https://doi.org/10.1093/gastro/gox031
Acknowledgements
The authors acknowledge financial support from the National Natural Science Foundation of China (Grant No. 81871976 to Xiaobo Li, Grant No. 81772498 to Yukuan Feng and Grant No. 31501158 to Jianhui Ma) and the Natural Science Foundation of Heilongjiang Province (Grant No. H2016006 to Xiaobo Li and Grant No. H2018009 to Tianzhen Wang).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
We declare that we have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhang, X., Feng, Y., Liu, X. et al. Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer. J Cancer Res Clin Oncol 145, 1387–1403 (2019). https://doi.org/10.1007/s00432-019-02902-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-02902-6